Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

DELSTRIGO

DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

Standard Dose
100MG;300MG;300MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview DELSTRIGO is listed in Drugs@FDA under application 210807 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE Form and strength TABLET;ORAL - 100MG;300MG;300MG Sponsor MSD MERCK CO Submission history Latest submission status date: 2025-10-29 00:00:00.

Structured Monograph

Clinical summary

Approval overview DELSTRIGO is listed in Drugs@FDA under application 210807 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE Form and strength TABLET;ORAL - 100MG;300MG;300MG Sponsor MSD MERCK CO Submission history Latest submission status date: 2025-10-29 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
DELSTRIGO (DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE) | Drug Monograph | MedicHelpline